The Impact of COVID-19 on People Living with HIV-1 and HIV-1-Associated Neurological Complications

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative pathogen of the coronavirus disease 2019 (COVID-19) pandemic, a fatal respiratory illness. The associated risk factors for COVID-19 are old age and medical comorbidities. In the current combined antiretroviral therapy (cART) era, a significant portion of people living with HIV-1 (PLWH) with controlled viremia is older and with comorbidities, making these people vulnerable to SARS-CoV-2 infection and COVID-19-associated severe outcomes. Additionally, SARS-CoV-2 is neurotropic and causes neurological complications, resulting in a health burden and an adverse impact on PLWH and exacerbating HIV-1-associated neurocognitive disorder (HAND). The impact of SARS-CoV-2 infection and COVID-19 severity on neuroinflammation, the development of HAND and preexisting HAND is poorly explored. In the present review, we compiled the current knowledge of differences and similarities between SARS-CoV-2 and HIV-1, the conditions of the SARS-CoV-2/COVID-19 and HIV-1/AIDS syndemic and their impact on the central nervous system (CNS). Risk factors of COVID-19 on PLWH and neurological manifestations, inflammatory mechanisms leading to the neurological syndrome, the development of HAND, and its influence on preexisting HAND are also discussed. Finally, we have reviewed the challenges of the present syndemic on the world population, with a particular emphasis on PLWH.

[1]  M. Augello,et al.  Immunologic Interplay Between HIV/AIDS and COVID-19: Adding Fuel to the Flames? , 2023, Current HIV/AIDS Reports.

[2]  G. Prince,et al.  SARS-CoV-2 infection augments species- and age-specific predispositions in cotton rats , 2023, Scientific Reports.

[3]  E. Topol,et al.  Long COVID: major findings, mechanisms and recommendations , 2023, Nature Reviews Microbiology.

[4]  A. Padovani,et al.  Looking for lights in the fog of long-term neurological COVID , 2022, Nature Reviews Neurology.

[5]  S. Arora,et al.  Clinical outcome of patients with HIV/SARS-COV-2 co-infection , 2022, Medical Journal Armed Forces India.

[6]  T. Woodruff,et al.  SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein , 2022, Molecular Psychiatry.

[7]  O. Polo,et al.  Saliva antibody-fingerprint of reactivated latent viruses after mild/asymptomatic COVID-19 is unique in patients with myalgic-encephalomyelitis/chronic fatigue syndrome , 2022, Frontiers in Immunology.

[8]  F. Dentali,et al.  Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications , 2022, eBioMedicine.

[9]  C. Demoliou,et al.  SARS-CoV-2 and HIV-1: So Different yet so Alike. Immune Response at the Cellular and Molecular Level , 2022, International journal of medical sciences.

[10]  Z. Al-Aly,et al.  Long-term neurologic outcomes of COVID-19 , 2022, Nature Medicine.

[11]  S. Shoptaw,et al.  Methamphetamine use and adoption of preventive behaviors early in the COVID-19 pandemic among men who have sex with men in Los Angeles, California , 2022, Drug and Alcohol Dependence Reports.

[12]  R. Radhakrishnan,et al.  Impact of Cannabis Use, Substance Use Disorders, and Psychiatric Diagnoses on COVID-19 Outcomes: A Retrospective Cohort Study. , 2022, The Journal of clinical psychiatry.

[13]  Doron Betel,et al.  SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8+ T-cells , 2022, Nature communications.

[14]  Gaurav,et al.  Putative role of mitochondria in SARS-CoV-2 mediated brain dysfunctions: a prospect. , 2022, Biotechnology & genetic engineering reviews.

[15]  M. Gandhi,et al.  COVID-19 Outcomes and Risk Factors Among People Living with HIV , 2022, Current HIV/AIDS Reports.

[16]  F. Ceccherini‐Silberstein,et al.  Neuro-Axonal Damage and Alteration of Blood–Brain Barrier Integrity in COVID-19 Patients , 2022, Cells.

[17]  S Spudich,et al.  Neuropathogenesis of HIV-1: insights from across the spectrum of acute through long-term treated infection , 2022, Seminars in Immunopathology.

[18]  W. Robinson,et al.  SARS-CoV-2 infection of monocytes: balancing acts of antibodies and inflammasomes , 2022, Signal Transduction and Targeted Therapy.

[19]  M. Peluso,et al.  Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection , 2022 .

[20]  T. Swartz,et al.  Inflammasomes as mediators of inflammation in HIV-1 infection. , 2022, Translational research : the journal of laboratory and clinical medicine.

[21]  Nishant Singh,et al.  COVID-19 Diagnosis: A Comprehensive Review of the RT-qPCR Method for Detection of SARS-CoV-2 , 2022, Diagnostics.

[22]  A. Rodrigues,et al.  SARS-CoV-2 seroprevalence among people living with HIV in Guinea–Bissau , 2022, Public Health.

[23]  Weiming Tang,et al.  Systematic Review and Meta-Analyses of The Interaction Between HIV Infection And COVID-19: Two Years’ Evidence Summary , 2022, Frontiers in Immunology.

[24]  Randolph D. Hubach,et al.  From crisis to crisis: impacts of the COVID-19 pandemic on people living with HIV and HIV/AIDS service organizations in Indiana , 2022, BMC Health Services Research.

[25]  K. Liang,et al.  COVID-19 Vaccination Willingness Among People Living With HIV in Wuhan, China , 2022, Frontiers in Public Health.

[26]  Y. Yazdanpanah,et al.  Risk Factors Associated with Severe/Critical COVID-19 in People Living with HIV-1 , 2022, International Journal of Infectious Diseases.

[27]  Ye-ming Wang,et al.  Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study , 2022, The Lancet Respiratory Medicine.

[28]  M. Boks,et al.  Characterization of HIV-1 Infection in Microglia-Containing Human Cerebral Organoids , 2022, Viruses.

[29]  Samuele Gardin,et al.  Factors Associated with Severe COVID-19 and Post-Acute COVID-19 Syndrome in a Cohort of People Living with HIV on Antiretroviral Treatment and with Undetectable HIV RNA , 2022, Viruses.

[30]  Sonia Tarazona,et al.  Association Between Sex Hormone Levels and Clinical Outcomes in Patients With COVID-19 Admitted to Hospital: An Observational, Retrospective, Cohort Study , 2022, Frontiers in Immunology.

[31]  J. Freer,et al.  HIV and covid-19 in South Africa , 2022, BMJ.

[32]  M. Safford,et al.  Health Status, Persistent Symptoms, and Effort Intolerance One Year After Acute COVID-19 Infection , 2022, Journal of General Internal Medicine.

[33]  A. Nath,et al.  Nervous system consequences of COVID-19 , 2022, Science.

[34]  Jinpyo Hong,et al.  SARS-CoV-2 spike protein induces cognitive deficit and anxiety-like behavior in mouse via non-cell autonomous hippocampal neuronal death , 2022, Scientific Reports.

[35]  Karan Varshney,et al.  Risk Factors for COVID-19 Mortality Among People Living with HIV: A Scoping Review , 2022, AIDS and Behavior.

[36]  Inyoul Y. Lee,et al.  Multiple early factors anticipate post-acute COVID-19 sequelae , 2022, Cell.

[37]  M. T. McIntosh,et al.  SARS-CoV-2 viroporin encoded by ORF3a triggers the NLRP3 inflammatory pathway , 2022, Virology.

[38]  T. Burki The origin of SARS-CoV-2 variants of concern , 2022, The Lancet. Infectious diseases.

[39]  Joohyun Park,et al.  Risk factors for COVID-19 among persons with substance use disorder (PWSUD) with hospital visits – United States, April 2020–December 2020 , 2022, Drug and Alcohol Dependence.

[40]  S. Maier,et al.  SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: Evidence of PAMP-like properties , 2021, Brain, Behavior, and Immunity.

[41]  F. Kobeissy,et al.  SARS-CoV-2 involvement in central nervous system tissue damage , 2021, Neural regeneration research.

[42]  S. Kent,et al.  Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection , 2021, medRxiv.

[43]  Tony Y. Hu,et al.  Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates , 2020, Nature Communications.

[44]  A. Salonia,et al.  Low testosterone levels predict clinical adverse outcomes in SARS‐CoV‐2 pneumonia patients , 2020, The Journal of Sexual Medicine.

[45]  H. Xiong,et al.  NLRP3 inflammasome activation and SARS-CoV-2-mediated hyperinflammation, cytokine storm and neurological syndromes. , 2022, International journal of physiology, pathophysiology and pharmacology.

[46]  Keshab Subedi,et al.  Characteristics and Outcomes of SARS-CoV-2 Infection Among Adults Living With HIV In Delaware: , 2021, Delaware journal of public health.

[47]  A. Tall,et al.  Modulation of the NLRP3 inflammasome by Sars-CoV-2 Envelope protein , 2021, Scientific Reports.

[48]  J. Lv,et al.  Role of asymptomatic and pre-symptomatic infections in covid-19 pandemic , 2021, BMJ.

[49]  E. Akıncı,et al.  Neurological Presentations in Patients with COVID-19 in Cytokine Storm , 2021, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[50]  O. Olajide,et al.  SARS-CoV-2 Spike Glycoprotein S1 Induces Neuroinflammation in BV-2 Microglia , 2021, Molecular Neurobiology.

[51]  G. Pentón-Rol,et al.  The microglial NLRP3 inflammasome is involved in human SARS-CoV-2 cerebral pathogenicity: A report of three post-mortem cases , 2021, Journal of Neuroimmunology.

[52]  A. Adimora,et al.  SARS-CoV-2 Infection Among People Living With HIV Compared to People Without HIV , 2021, JAIDS Journal of Acquired Immune Deficiency Syndromes.

[53]  Maaged A Akiel,et al.  SARS-CoV-2 Coronavirus Spike Protein-Induced Apoptosis, Inflammatory, and Oxidative Stress Responses in THP-1-Like-Macrophages: Potential Role of Angiotensin-Converting Enzyme Inhibitor (Perindopril) , 2021, Frontiers in Immunology.

[54]  Z. Rao,et al.  Structural biology of SARS-CoV-2 and implications for therapeutic development , 2021, Nature Reviews Microbiology.

[55]  Steven C. Johnson,et al.  HIV and COVID-19: review of clinical course and outcomes , 2021, HIV research & clinical practice.

[56]  J. Zoladz,et al.  Lowered Serum Testosterone Concentration Is Associated With Enhanced Inflammation and Worsened Lipid Profile in Men , 2021, Frontiers in Endocrinology.

[57]  Wenfang Wang,et al.  A dual-role of SARS-CoV-2 nucleocapsid protein in regulating innate immune response , 2021, Signal Transduction and Targeted Therapy.

[58]  A. Sigalov SARS-CoV-2 may affect the immune response via direct inhibition of T cell receptor: Mechanistic hypothesis and rationale , 2021, Biochimie.

[59]  Jianguo Wu,et al.  SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation , 2021, Nature Communications.

[60]  S. Olatunji,et al.  Comorbidities and Risk Factors for Severe Outcomes in COVID-19 Patients in Saudi Arabia: A Retrospective Cohort Study , 2021, Journal of multidisciplinary healthcare.

[61]  J. Olivares,et al.  Microglia: The Real Foe in HIV-1-Associated Neurocognitive Disorders? , 2021, Biomedicines.

[62]  R. Zhou,et al.  NLRP3 inflammasome activation and cell death , 2021, Cellular & Molecular Immunology.

[63]  Weitao Li,et al.  SARS‐CoV‐2 nucleocapsid suppresses host pyroptosis by blocking Gasdermin D cleavage , 2021, The EMBO journal.

[64]  Christopher M. Jones,et al.  Substance Use among Men Who Have Sex with Men. , 2021, The New England journal of medicine.

[65]  D. Leach,et al.  The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells , 2021, Nature Communications.

[66]  M. VanElzakker,et al.  Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms , 2021, Frontiers in Microbiology.

[67]  Shruti Gupta,et al.  Interleukin-6 Perpetrator of the COVID-19 Cytokine Storm , 2021, Indian Journal of Clinical Biochemistry.

[68]  M. Hallek,et al.  Long‐lived macrophage reprogramming drives spike protein‐mediated inflammasome activation in COVID‐19 , 2021, EMBO molecular medicine.

[69]  L. Kang,et al.  A Review of Neurological Involvement in Patients with SARS-CoV-2 Infection , 2021, Medical science monitor : international medical journal of experimental and clinical research.

[70]  S. Pujari,et al.  Long‐coronavirus disease among people living with HIV in western India: An observational study , 2021, Immunity, inflammation and disease.

[71]  D. Kell,et al.  Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin , 2021, Cardiovascular Diabetology.

[72]  D. Kuritzkes,et al.  COVID-19 and HIV infection co-pandemics and their impact: a review of the literature , 2021, AIDS Research and Therapy.

[73]  Yang Guo,et al.  Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration , 2021, Frontiers in Immunology.

[74]  Xiaozhong Peng,et al.  The olfactory route is a potential way for SARS-CoV-2 to invade the central nervous system of rhesus monkeys , 2021, Signal Transduction and Targeted Therapy.

[75]  G. Lanzieri,et al.  Sex-differences in COVID-19 associated excess mortality is not exceptional for the COVID-19 pandemic , 2021, Scientific Reports.

[76]  M. Adelman,et al.  Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy , 2021, Annals of Internal Medicine.

[77]  M. Hernán,et al.  Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy , 2021, Annals of Internal Medicine.

[78]  K. Pruitt,et al.  SARS-CoV-2 and Human Immunodeficiency Virus: Pathogen Pincer Attack , 2021, HIV/AIDS.

[79]  V. Chinchilli,et al.  Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis , 2021, Scientific Reports.

[80]  S. Spector,et al.  SARS-CoV-2, SARS-CoV-1, and HIV-1 derived ssRNA sequences activate the NLRP3 inflammasome in human macrophages through a non-classical pathway , 2021, iScience.

[81]  D. Saylor,et al.  HIV in the Brain , 2021, Neurology.

[82]  M. Adesina,et al.  COVID‐19: Learning from the HIV/AIDS pandemic response in Africa , 2021, The International journal of health planning and management.

[83]  E. Engler-Chiurazzi,et al.  SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders , 2021, Cytokine & Growth Factor Reviews.

[84]  M. Montano PRESSING QUESTIONS AND CHALLENGES IN THE HIV-1 AND SARS-COV-2 SYNDEMIC. , 2021, AIDS research and human retroviruses.

[85]  Alaa Al-hindawi,et al.  Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone , 2021, Inflammation.

[86]  M. Lasso,et al.  Clinical characteristics and outcomes of people living with HIV hospitalized with COVID-19: a nationwide experience , 2021, International journal of STD & AIDS.

[87]  Benjamin Bowe,et al.  High-dimensional characterization of post-acute sequelae of COVID-19 , 2021, Nature.

[88]  J. Hochman,et al.  C-reactive protein and clinical outcomes in patients with COVID-19 , 2021, European heart journal.

[89]  S. Farhadian,et al.  Neuroinvasion of SARS-CoV-2 in human and mouse brain , 2021, The Journal of experimental medicine.

[90]  T. Solomon Neurological infection with SARS-CoV-2 — the story so far , 2021, Nature Reviews Neurology.

[91]  J. Girón-González,et al.  Similarities and differences between HIV and SARS-CoV-2 , 2021, International journal of medical sciences.

[92]  K. Bhaskaran,et al.  HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform , 2020, The Lancet HIV.

[93]  D. Perl,et al.  Microvascular Injury in the Brains of Patients with Covid-19 , 2020, The New England journal of medicine.

[94]  J. Lazarus,et al.  HIV care models during the COVID-19 era , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[95]  S. Lucas Pandemics and pathology: a reflection on influenza, HIV/AIDS and SARS (COVID-19) pandemic infections , 2020, Diagnostic Histopathology.

[96]  J. Routy,et al.  Sharing CD4+ T Cell Loss: When COVID-19 and HIV Collide on Immune System , 2020, Frontiers in Immunology.

[97]  C. Conrad,et al.  Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19 , 2020, Nature Neuroscience.

[98]  Hongyu Zhao,et al.  Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men , 2020, Cell Stem Cell.

[99]  J. Margolick,et al.  COVID-19 symptoms and SARS-CoV-2 infection among people living with HIV in the US: the MACS/WIHS combined cohort study , 2020, HIV research & clinical practice.

[100]  Rowena Johnston The first 6 months of HIV-SARS-CoV-2 coinfection: outcomes for 6947 individuals , 2020, Current opinion in HIV and AIDS.

[101]  M. Raji,et al.  The Impact of Substance Use Disorder on COVID-19 Outcomes. , 2020, Psychiatric services.

[102]  N. Arinaminpathy,et al.  The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis , 2020, EClinicalMedicine.

[103]  A. Helenius,et al.  Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity , 2020, Science.

[104]  J. Mehta,et al.  Hypothesis: Sex-Related Differences in ACE2 Activity May Contribute to Higher Mortality in Men Versus Women With COVID-19 , 2020, Journal of cardiovascular pharmacology and therapeutics.

[105]  N. Kumarasamy,et al.  Impact of COVID-19 on people living with HIV: A review , 2020, Journal of Virus Eradication.

[106]  A. Andrews,et al.  The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood–brain barrier , 2020, Neurobiology of Disease.

[107]  Bilal Ahmad,et al.  Emergence and molecular mechanisms of SARS-CoV-2 and HIV to target host cells and potential therapeutics , 2020, Infection, Genetics and Evolution.

[108]  I. Koralnik,et al.  Frequent neurologic manifestations and encephalopathy‐associated morbidity in Covid‐19 patients , 2020, Annals of clinical and translational neurology.

[109]  M. Aepfelbacher,et al.  Neuropathology of patients with COVID-19 in Germany: a post-mortem case series , 2020, The Lancet Neurology.

[110]  B. Fielding,et al.  Insult to injury- potential contribution of COVID-19 to neuroinflammation and the development of HIV-associated neurocognitive disorders. , 2020, AIDS research and human retroviruses.

[111]  Catherine Z. Chen,et al.  Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium , 2020, Cell Stem Cell.

[112]  A. Okoh,et al.  Clinical outcomes of patients with COVID‐19 and HIV coinfection , 2020, Journal of medical virology.

[113]  N. Volkow,et al.  COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States , 2020, Molecular Psychiatry.

[114]  C. Iwu,et al.  Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-infection with HIV: clinical case series analysis in North Central Nigeria , 2020, The Pan African medical journal.

[115]  F. Hashmi,et al.  Concerns of HIV-positive migrant workers in COVID-19 pandemic: A call for action , 2020, Journal of global health.

[116]  J. Choreño-Parra,et al.  Neurological Aspects of SARS-CoV-2 Infection: Mechanisms and Manifestations , 2020, Frontiers in Neurology.

[117]  C. Scagnolari,et al.  Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection , 2020, Medicine.

[118]  J. Becker,et al.  Studying the neuropsychological sequelae of SARS-CoV-2: lessons learned from 35 years of neuroHIV research , 2020, Journal of NeuroVirology.

[119]  S. Farhadian,et al.  Sex differences in immune responses that underlie COVID-19 disease outcomes , 2020, Nature.

[120]  Mark E. Howard,et al.  Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June 24–30, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[121]  Y. Hadi,et al.  Characteristics and outcomes of COVID-19 in patients with HIV: a multi-center research network study. , 2020, AIDS.

[122]  R. Glaubius,et al.  Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models , 2020, The lancet. HIV.

[123]  V. Garovic,et al.  COVID-19 and Sex Differences , 2020, Mayo Clinic Proceedings.

[124]  R. Bhopal,et al.  Sex differential in COVID-19 mortality varies markedly by age , 2020, The Lancet.

[125]  J. Gomes,et al.  Neuropathogenesis of SARS-CoV-2 infection , 2020, eLife.

[126]  M. Arosio,et al.  SARS‐CoV‐2 infection in persons living with HIV: A single center prospective cohort , 2020, Journal of medical virology.

[127]  Dhavan V. Shah,et al.  Potential Influences of the COVID-19 Pandemic on Drug Use and HIV Care Among People Living with HIV and Substance Use Disorders: Experience from a Pilot mHealth Intervention , 2020, AIDS and Behavior.

[128]  H. Gendelman,et al.  The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections , 2020, Journal of Neuroimmune Pharmacology.

[129]  P. Adadi,et al.  HIV/SARS‐CoV‐2 coinfection: A global perspective , 2020, Journal of medical virology.

[130]  Yangang Wang,et al.  Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis , 2020, International Journal of Infectious Diseases.

[131]  J. Schneider,et al.  What HIV in the brain can teach us about SARS-CoV-2 neurologic complications? , 2020, AIDS research and human retroviruses.

[132]  G. Paolisso,et al.  Covid-19 Kills More Men Than Women: An Overview of Possible Reasons , 2020, Frontiers in Cardiovascular Medicine.

[133]  B. Woodward,et al.  Coronavirus disease 2019 (COVID‐19) outcomes in HIV/AIDS patients: a systematic review , 2020, HIV medicine.

[134]  H. Khorramdelazad,et al.  The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics , 2020, Life Sciences.

[135]  G. Pokhrel,et al.  Neurological manifestations of COVID-19: a systematic review , 2020, Critical Care.

[136]  A. Manini,et al.  Opioid Use Disorder and COVID-19: Biological Plausibility for Worsened Outcomes , 2020, Substance use & misuse.

[137]  B. Mulsant,et al.  COVID-19 and persons with substance use disorders: Inequities and mitigation strategies , 2020, Substance abuse.

[138]  P. Lara,et al.  Age-induced NLRP3 Inflammasome Over-activation Increases Lethality of SARS-CoV-2 Pneumonia in Elderly Patients , 2020, Aging and disease.

[139]  S. Friedman,et al.  Challenges posed by COVID‐19 to people who inject drugs and lessons from other outbreaks , 2020, Journal of the International AIDS Society.

[140]  M. Peluso,et al.  Clinical outcomes and immunologic characteristics of Covid-19 in people with HIV. , 2020, The Journal of infectious diseases.

[141]  V. Valcour,et al.  Associations Between Plasma Immunomodulatory and Inflammatory Mediators With VACS Index Scores Among Older HIV-Infected Adults on Antiretroviral Therapy , 2020, Frontiers in Immunology.

[142]  Hong-Wei Sun,et al.  Sex differences in neutrophil biology modulate response to type I interferons and immunometabolism , 2020, Proceedings of the National Academy of Sciences.

[143]  L. Smirnova,et al.  Infectability of human BrainSphere neurons suggests neurotropism of SARS-CoV-2. , 2020, ALTEX.

[144]  M. Hernán,et al.  Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy , 2020, Annals of Internal Medicine.

[145]  Pardis C Sabeti,et al.  Neuropathological Features of Covid-19 , 2020, The New England journal of medicine.

[146]  Madeline A. Lancaster,et al.  Human CNS barrier-forming organoids with cerebrospinal fluid production , 2020, Science.

[147]  S. Klein,et al.  Considering how biological sex impacts immune responses and COVID-19 outcomes , 2020, Nature Reviews Immunology.

[148]  A. Caliendo,et al.  Intersecting Pandemics: Impact of SARS-CoV-2 (COVID-19) Protective Behaviors on People Living With HIV, Atlanta, Georgia , 2020, Journal of acquired immune deficiency syndromes.

[149]  P. Adadi,et al.  Living with HIV in the time of COVID‐19: A glimpse of hope , 2020, Journal of medical virology.

[150]  X. Mao,et al.  Vascular Endothelial Growth Factor (VEGF) as a Vital Target for Brain Inflammation during the COVID-19 Outbreak. , 2020, ACS chemical neuroscience.

[151]  C. Ruiz,et al.  SARS-CoV-2 infection: The role of cytokines in COVID-19 disease , 2020, Cytokine & Growth Factor Reviews.

[152]  M. Horberg,et al.  Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016 , 2020, JAMA network open.

[153]  I. Holloway,et al.  COVID‐19 vulnerability among people who use drugs: recommendations for global public health programmes and policies , 2020, Journal of the International AIDS Society.

[154]  Noga Shalev,et al.  Clinical Characteristics and Outcomes in People Living With Human Immunodeficiency Virus Hospitalized for Coronavirus Disease 2019 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[155]  Dan J Stein,et al.  Peripheral immune dysregulation in the ART era of HIV-associated neurocognitive impairments: A systematic review , 2020, Psychoneuroendocrinology.

[156]  Zhi-qiang Zhou,et al.  Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms , 2020, Journal of Neurology.

[157]  R. King,et al.  “Everything is a Mess”: How COVID-19 is Impacting Engagement with HIV Testing Services in Rural Southwestern Uganda , 2020, AIDS and Behavior.

[158]  The Lancet Hiv Lockdown fears for key populations , 2020, The Lancet HIV.

[159]  P. Carmeliet,et al.  COVID-19: the vasculature unleashed , 2020, Nature Reviews Immunology.

[160]  A. Harky,et al.  Neurological Manifestations of COVID-19: A review. , 2020, Acta neurologica Scandinavica.

[161]  S. Kuchukhidze,et al.  COVID-19, HIV, and Migrant Workers: The Double Burden of the Two Viruses. , 2020, AIDS patient care and STDs.

[162]  A. Giacomelli,et al.  Clinical features and outcomes of HIV patients with coronavirus disease 2019 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[163]  Victor G. Puelles,et al.  Multiorgan and Renal Tropism of SARS-CoV-2 , 2020, The New England journal of medicine.

[164]  B. Lambert,et al.  What does the COVID-19 pandemic mean for HIV, tuberculosis, and malaria control? , 2020, Tropical Medicine and Health.

[165]  A. Horban,et al.  HIV care in times of the COVID-19 crisis — Where are we now in Central and Eastern Europe? , 2020, International Journal of Infectious Diseases.

[166]  Garima Sharma,et al.  Sex Differences in Mortality From COVID-19 Pandemic , 2020, JACC: Case Reports.

[167]  C. Hopkins,et al.  Early recovery following new onset anosmia during the COVID-19 pandemic – an observational cohort study , 2020, Journal of Otolaryngology - Head & Neck Surgery.

[168]  R. Pinto,et al.  COVID-19 Pandemic Disrupts HIV Continuum of Care and Prevention: Implications for Research and Practice Concerning Community-Based Organizations and Frontline Providers , 2020, AIDS and Behavior.

[169]  C. Macintyre,et al.  Public health, health systems and palliation planning for COVID‐19 on an exponential timeline , 2020, The Medical journal of Australia.

[170]  Kristen D. Krause,et al.  The Burden of COVID-19 in People Living with HIV: A Syndemic Perspective , 2020, AIDS and Behavior.

[171]  Carl H. June,et al.  Cytokine release syndrome in severe COVID-19 , 2020, Science.

[172]  Felipe García,et al.  COVID-19 in patients with HIV: clinical case series , 2020, The Lancet HIV.

[173]  Daeui Park,et al.  Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor , 2020, ACS nano.

[174]  C. Conrad,et al.  SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. , 2020, The EMBO journal.

[175]  R. Butowt,et al.  SARS-CoV-2: Olfaction, Brain Infection, and the Urgent Need for Clinical Samples Allowing Earlier Virus Detection , 2020, ACS chemical neuroscience.

[176]  Q. Ye,et al.  The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 , 2020, Journal of Infection.

[177]  L. Mao,et al.  Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. , 2020, JAMA neurology.

[178]  Zhigang Wu,et al.  Molecular Architecture of the SARS-CoV-2 Virus , 2020, Cell.

[179]  N. Enomoto,et al.  A first case of meningitis/encephalitis associated with SARS-Coronavirus-2 , 2020, International Journal of Infectious Diseases.

[180]  A. Verkhratsky,et al.  Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID‐19 , 2020, Acta physiologica.

[181]  Russell B. Fletcher,et al.  Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia , 2020, Science Advances.

[182]  A. Giacomelli,et al.  Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[183]  Xiaowei Li,et al.  Molecular immune pathogenesis and diagnosis of COVID-19 , 2020, Journal of Pharmaceutical Analysis.

[184]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[185]  A. M. Leontovich,et al.  The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 , 2020, Nature Microbiology.

[186]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[187]  Bo Diao,et al.  Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Immunology.

[188]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[189]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[190]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[191]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[192]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[193]  Dong-Yan Jin,et al.  A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses , 2020, Emerging microbes & infections.

[194]  M. Villacres,et al.  Loss of Pre-Existing Immunological Memory among HIV Infected Women Despite Immune Reconstitution with Antiretroviral Therapy. , 2019, The Journal of infectious diseases.

[195]  C. Van Lint,et al.  Microglial Cells: The Main HIV-1 Reservoir in the Brain , 2019, Front. Cell. Infect. Microbiol..

[196]  E. Masliah,et al.  NLRP3-dependent pyroptosis is required for HIV-1 gp120-induced neuropathology , 2019, Cellular & Molecular Immunology.

[197]  Yuan He,et al.  The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation , 2019, International journal of molecular sciences.

[198]  P. Palma,et al.  Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART , 2019, Viruses.

[199]  I. Grant,et al.  Cerebrospinal Fluid Ceruloplasmin, Haptoglobin, and Vascular Endothelial Growth Factor Are Associated with Neurocognitive Impairment in Adults with HIV Infection , 2018, Molecular Neurobiology.

[200]  Shengdi Chen,et al.  Blood-Brain Barrier Disruption Induced Cognitive Impairment Is Associated With Increase of Inflammatory Cytokine , 2018, Front. Aging Neurosci..

[201]  D. Swendeman,et al.  Mental Health and Substance Use Disorder Comorbidity among Methamphetamine-Using Men Who have Sex with Men , 2018, Journal of psychoactive drugs.

[202]  M. Young,et al.  Variability in C-reactive protein is associated with cognitive impairment in women living with and without HIV: a longitudinal study , 2018, Journal of NeuroVirology.

[203]  R. Hogg,et al.  Health-adjusted life expectancy in HIV-positive and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study. , 2017, The lancet. HIV.

[204]  Mark Obermann,et al.  HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment , 2017, Journal of Neurology.

[205]  B. Maughan-Brown,et al.  Improved life expectancy of people living with HIV: who is left behind? , 2017, The lancet. HIV.

[206]  M. Gougeon Alarmins and central nervous system inflammation in HIV‐associated neurological disorders , 2017, Journal of internal medicine.

[207]  S. Buch,et al.  HIV-1 Tat Primes and Activates Microglial NLRP3 Inflammasome-Mediated Neuroinflammation , 2017, The Journal of Neuroscience.

[208]  W. Stenzel,et al.  Acute and chronic viral infections. , 2017, Handbook of clinical neurology.

[209]  S. Lewin,et al.  HIV persistence and T-cell activation in blood, rectal and lymph node tissue in HIV-infected individuals receiving suppressive ART. , 2017, The Journal of infectious diseases.

[210]  N. Nakasujja,et al.  Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, Uganda , 2016, Journal of NeuroVirology.

[211]  C. Power,et al.  HIV-1 Viral Protein R Activates NLRP3 Inflammasome in Microglia: implications for HIV-1 Associated Neuroinflammation , 2017, Journal of Neuroimmune Pharmacology.

[212]  J. Margolick,et al.  Effect of HIV-infection and cumulative viral load on age-related decline in grip strength , 2016, AIDS.

[213]  A. Winston,et al.  Defining cognitive impairment in people-living-with-HIV: the POPPY study , 2016, BMC Infectious Diseases.

[214]  Jerome H. Kim,et al.  Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV-infected individuals , 2016, AIDS.

[215]  David J. Volsky,et al.  HIV-associated neurocognitive disorder — pathogenesis and prospects for treatment , 2016, Nature Reviews Neurology.

[216]  M. Saleem,et al.  HIV Promotes NLRP3 Inflammasome Complex Activation in Murine HIV-Associated Nephropathy. , 2016, The American journal of pathology.

[217]  Jonathan Kipnis,et al.  Revisiting the Mechanisms of CNS Immune Privilege. , 2015, Trends in immunology.

[218]  A. Phillips,et al.  Factors Associated With Plasma IL-6 Levels During HIV Infection. , 2015, The Journal of infectious diseases.

[219]  Paul E. Gilbert,et al.  Elevated rates of mild cognitive impairment in HIV disease , 2015, Journal of NeuroVirology.

[220]  D. McGavern,et al.  Viral diseases of the central nervous system. , 2015, Current opinion in virology.

[221]  Meng Xu,et al.  The Relationship of CSF and Plasma Cytokine Levels in HIV Infected Patients with Neurocognitive Impairment , 2015, BioMed research international.

[222]  I. Grant,et al.  Abdominal Obesity Contributes to Neurocognitive Impairment in HIV-Infected Patients With Increased Inflammation and Immune Activation , 2015, Journal of acquired immune deficiency syndromes.

[223]  G. Guaraldi,et al.  Hypogonadism in the HIV-infected man. , 2014, Endocrinology and metabolism clinics of North America.

[224]  G. Guaraldi,et al.  Multimorbidity and functional status assessment. , 2014, Current opinion in HIV and AIDS.

[225]  M. Lederman,et al.  HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality , 2014, PLoS pathogens.

[226]  Maureen H Richards,et al.  β-Catenin/TCF-4 signaling regulates susceptibility of macrophages and resistance of monocytes to HIV-1 productive infection. , 2014, Current HIV research.

[227]  P. Böelle,et al.  Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[228]  A. Lorenc,et al.  The prevalence of comorbidities among people living with HIV in Brent: a diverse London Borough , 2014, London journal of primary care.

[229]  James J. Goedert,et al.  Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada , 2013, PloS one.

[230]  K. Tashima,et al.  Relationship of plasma cytokines and clinical biomarkers to memory performance in HIV , 2013, Journal of Neuroimmunology.

[231]  B. Ances,et al.  HIV-associated neurocognitive disorder. , 2013, The Lancet. Infectious diseases.

[232]  D. Douek,et al.  Systemic effects of inflammation on health during chronic HIV infection. , 2013, Immunity.

[233]  Jennifer A. Pellowski,et al.  A pandemic of the poor: social disadvantage and the U.S. HIV epidemic. , 2013, The American psychologist.

[234]  N. Ford,et al.  Life Expectancy of Persons Receiving Combination Antiretroviral Therapy in Low-Income Countries: A Cohort Analysis From Uganda , 2011, Annals of Internal Medicine.

[235]  J. Nachega,et al.  HIV treatment adherence, drug resistance, virologic failure: Evolving concepts , 2022 .

[236]  R. Ownby,et al.  Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains , 2009, Journal of NeuroVirology.

[237]  Andrew V. Albright,et al.  Pathogenesis of human immunodeficiency virus-induced neurological disease , 2003, Journal of NeuroVirology.

[238]  F. Sutterwala,et al.  The NLRP3 inflammasome: a sensor of immune danger signals. , 2009, Seminars in immunology.

[239]  S. Mahajan,et al.  SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-κB pathway in human monocyte macrophages in vitro , 2009, Virus Research.

[240]  Ross J. Harris,et al.  Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies , 2008, The Lancet.

[241]  David K. Meyerholz,et al.  Severe Acute Respiratory Syndrome Coronavirus Infection Causes Neuronal Death in the Absence of Encephalitis in Mice Transgenic for Human ACE2 , 2008, Journal of Virology.

[242]  J. Becker,et al.  Updated research nosology for HIV-associated neurocognitive disorders , 2007, Neurology.

[243]  E. Lazartigues,et al.  Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[244]  T. Kielian Toll‐like receptors in central nervous system glial inflammation and homeostasis , 2006, Journal of neuroscience research.

[245]  N. Zhong,et al.  Detection of Severe Acute Respiratory Syndrome Coronavirus in the Brain: Potential Role of the Chemokine Mig in Pathogenesis , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[246]  Francisco González-Scarano,et al.  The neuropathogenesis of AIDS , 2005, Nature Reviews Immunology.

[247]  Jeffrey N. Martin,et al.  Central Memory CD4+ T Cell Responses in Chronic HIV Infection Are Not Restored by Antiretroviral Therapy1 , 2004, The Journal of Immunology.

[248]  E. Lavi,et al.  Coronavirus Neurovirulence Correlates with the Ability of the Virus To Induce Proinflammatory Cytokine Signals from Astrocytes and Microglia , 2004, Journal of Virology.

[249]  H. Gendelman,et al.  Mononuclear phagocyte immunity and the neuropathogenesis of HIV‐1 infection , 2003, Journal of leukocyte biology.

[250]  Y. Shoenfeld,et al.  HIV and autoimmunity. , 2002, Autoimmunity reviews.

[251]  F. Scaravilli,et al.  Early entry and widespread cellular involvement of HIV-1 DNA in brains of HIV-1 positive asymptomatic individuals. , 1999, Journal of neuropathology and experimental neurology.

[252]  M. Weinand,et al.  A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. , 1997, Journal of immunology.

[253]  H. Gendelman,et al.  Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. , 1996, Journal of immunology.

[254]  J. Clements,et al.  Molecular biology and pathogenesis of animal lentivirus infections , 1996, Clinical microbiology reviews.

[255]  Robin A. Weiss,et al.  How does HIV cause AIDS , 1993 .

[256]  W. Wachsman,et al.  Early viral brain invasion in iatrogenic human immunodeficiency virus infection , 1992, Neurology.

[257]  P. Carrieri,et al.  Interleukin-6 and granulocyte macrophage-CSF in the cerebrospinal fluid from HIV infected subjects with involvement of the central nervous system. , 1992, Arquivos de neuro-psiquiatria.

[258]  L. Resnick,et al.  Early penetration of the blood‐brain‐barrier by HIV , 1988, Neurology.

[259]  C. Wiley,et al.  Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[260]  A. Haase Pathogenesis of lentivirus infections , 1986, Nature.

[261]  R. Schooley,et al.  Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. , 1985, The New England journal of medicine.

[262]  Michael S. B. Edwards,et al.  A Trojan Horse mechanism for the spread of visna virus in monocytes. , 1985, Virology.

[263]  D. Longo,et al.  Acquired Immunodeficiency Syndrome: Epidemiologic, Clinical, Immunologic, and Therapeutic Considerations , 1984 .